Eli Lilly and Company (TSX:LLY)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.53T +76.3% |
| Revenue (ttm) | 113.13B +49.6% |
| Net Income | 37.93B +93.6% |
| EPS | 42.30 +94.8% |
| Shares Out | n/a |
| PE Ratio | 40.28 |
| Forward PE | 31.50 |
| Dividend | 0.24 (0.53%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 75,322 |
| Open | 45.66 |
| Previous Close | 45.88 |
| Day's Range | 44.54 - 45.79 |
| 52-Week Range | 25.10 - 46.26 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Eli Lilly files six new lawsuits in effort to shutdown retatrutide black market
Eli Lilly (LLY) escalated its continued fight to protect patients from the black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to havi...
OmniAb announces collaboration and license agreement with Eli Lilly
OmniAb (OABI) announced a global collaboration and license agreement with Eli Lilly and Company (LLY) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expert...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Novo CEO says obesity market won't be winner-take-all battle with Lilly
Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-tak...
Novo Nordisk CEO defends lawsuit against Eli Lilly: 'Competition has to be fair'
Novo Nordisk CEO Mike Doustdar defended the drugmaker's decision to sue rival Eli Lilly over its weight-loss drug advertising. "I am a big fan of competition.
Eli Lilly is suing pharmacies and peptide vendors over early sales of the next big weight-loss drug: retatrutide
Some Americans have turned to medical spas and pharmacies that sell peptides for health and wellness benefits for access to compounded versions of retatrutide.
Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs
Eli Lilly has filed six new lawsuits against U.S. entities that it alleges are selling a version of the company's investigational weight-loss drug on the black market.
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide
Eli Lilly on Wednesday said it had filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide, escalating its campaig...
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
Files six new lawsuits as company escalates fight to protect patients INDIANAPOLIS, Aug. 12, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patie...
Veeva says Eli Lilly has committed to Veeva Vault CRM globally
Veeva Systems (VEEV) announced that Eli Lilly and Company (LLY) has committed to Veeva Vault CRM globally. Vault CRM is part of the Vault CRM Suite of applications that provides…
Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.
Eli Lilly's Foundayo won U.K. approval, becoming Europe's second GLP-1 weight-loss pill and its first approval outside the U.S. Foundayo will initially be available privately by prescription, with NHS...
MHRA authorizes Eli Lilly’s weight loss pill Foundayo in UK
Britain’s Medicines and Healthcare products Regulatory Agency has authorized Eli Lilly’s (LLY) orforglipron, or Foundayo, making the UK the first country in Europe to approve this GLP-1 tablet for wei...
UK green lights Lilly's obesity pill
The British medicines regulator on Monday authorised Eli Lilly's pill Foundayo for weight management and type 2 diabetes, becoming Europe's first country to do so.
Nvidia, Eli Lilly, and Disney Show It's Time to Back the Top Dogs
Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now.
Broad Market Momentum & Defensive Pivots: This Week's Top ETF Flows
The ETF market saw a massive surge into core index heavyweights this past week, as investors poured billions into broad U.S. equities and mega-cap tech leadership. However, this aggressive accumulatio...
Eli Lilly price target raised to $1,376 from $1,370 at Truist
Truist raised the firm’s price target on Eli Lilly (LLY) to $1,376 from $1,370 and keeps a Buy rating on the shares. Eli Lilly delivered strong Q2 performance with substantial…
Jim Cramer highlights 5 investing themes — and the stocks to buy for each
CNBC's Jim Cramer said earnings season reinforced five investing themes he thinks will produce the market's best buying opportunities. He highlighted stocks to buy for each theme, including Capital On...
The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
Both Eli Lilly and Novo Nordisk beat second-quarter estimates and raised their full-year outlooks. But while investors cheered Lilly's results, they punished Novo a day earlier – underscoring a growin...
Eli Lilly price target raised to $1,410 from $1,350 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Eli Lilly (LLY) to $1,410 from $1,350 and keeps an Overweight rating on the shares. Eli Lilly delivered a strong Q2 with…
Eli Lilly price target raised to $1,419 from $1,347 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,419 from $1,347 and keeps an Overweight rating on the shares. The firm views Lilly’s Q2 results and…
Eli Lilly price target raised to $1,400 from $1,300 at BMO Capital
BMO Capital analyst Evan Seigerman raised the firm’s price target on Eli Lilly (LLY) to $1,400 from $1,300 and keeps an Outperform rating on the shares. The company delivered a…
Eli Lilly price target raised to $1,330 from $1,280 at Wells Fargo
Wells Fargo analyst Mohit Bansal raised the firm’s price target on Eli Lilly (LLY) to $1,330 from $1,280 and keeps an Overweight rating on the shares. The firm believes the…